Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12168032 | 0.81 | LMNA (0.35) | TDP1LMNAHTTALDH1A1KMT2A | |
| SCHEMBL7623081 | 0.81 | TYR (0.50) | LMNAHTTALDH1A1IDO1 | |
| SCHEMBL13631877 | 0.81 | HDAC8 (0.32) | TDP1LMNAHDAC8HDAC6 | |
| SCHEMBL3172290 | 0.79 | IDO1 (0.34) | AOC3HTTIDO1TDO2HDAC3 | |
| SCHEMBL29232992 | 0.79 | HDAC3 (0.38) | LMNAAOC3HTTALDH1A1IDO1 | |
| SCHEMBL23580752 | 0.79 | ADRB2 (0.40) | TDP1LMNAAOC3HTT | |
| SCHEMBL9714748 | 0.79 | ESR1 (0.54) | TDP1LMNAALDH1A1 | |
| SCHEMBL19060475 | 0.79 | CYP1A2 (0.38) | ALDH1A1HDAC8HDAC6 | |
| SCHEMBL11285019 | 0.79 | L3MBTL1 (0.45) | TDP1LMNAALDH1A1CYP17A1IDO1 | |
| SCHEMBL218804 | 0.78 | LMNA (0.46) | LMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376056-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4366829-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117957212-A | IL-17A modulators based on phenylacetamide and uses thereof | 戴斯阿尔法公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| CN-106414398-B | Compound, active energy ray-curable composition, cured product thereof, printing ink, and ink for inkjet recording | DIC株式会社 | 2019-04-05 | — | — | CN | disclosed |
| CN-109153653-A | New compound, Photocurable composition, its solidfied material, printing ink and the printed article for having used the printing ink | DIC株式会社 | 2019-01-04 | — | — | CN | disclosed |
| EP-2627178-B1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| CN-106414398-A | Compound, active energy ray-curable composition, cured product thereof, printing ink, and ink for inkjet recording | DIC株式会社 | 2017-02-15 | — | — | CN | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2627178-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012051036-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012051036-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | WO | disclosed |
| CN-102292319-A | Novel substituted octahydrocyclopenta(C)pyrrol-4-amines as calcium channel blockers | — | 2011-12-21 | — | — | CN | disclosed |
| US-5102899-A | AZOLYLMETHYLOXIRANES AND FUNGICIDES CONTAINING THEM | BASF AKTIENGESELLSCHAFT (DE) | 1992-04-07 | — | — | US | disclosed |
| EP-0330016-A2 | Azolyl methyl oxiranes and fungicides containing them | BASF Aktiengesellschaft (DE) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, NR3C2, HRH1 | TDP1 4803/4885LMNA 3867/4885AOC3 3515/4885 |
| US-20240376056-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | IL17A, IL1A, IL2 | TDP1 4472/4885LMNA 4386/4885AOC3 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.